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1. Introduction
Rheumatoid arthritis (RA) is a chronic multi-system inflammatory autoim-
mune disease of indefinite etiology. The disease primarily affects synovial joints 
eventually progressing to ongoing inflammation, destruction of both cartilaginous 
and bony elements of the joint, with resultant pain and disability. The disease 
additionally displays a spectrum of extra-articular multisystem manifestations 
[1]. The worldwide prevalence of RA remains underestimated, data gathered from 
Western regions illustrated prevalence between 0.5 and 1% in white individu-
als, with prevalence rates ranging between 0.6 and 0.9% in the studied black 
individuals. The female to male ratio in rheumatoid arthritis is 2:1 to 3:1. A high 
concordance rate is observed in monozygotic twins 12–15% compared to 2–3% in 
dizygotic twins [2–4].
Theories behind the evolution of autoimmunity in rheumatoid arthritis are 
clearly multifactorial. The inflammatory process usually develops in a predisposed 
individual who is probably exposed to a provocative trigger of autoimmunity via 
epigenetic modifications. A number of risk factors comprising genetic as well non 
genetic elements provide the hostile environment for the change towards autoim-
munity. Evidences revealed a significant impact of familial genetic risk factors 
featuring ≥50% of the total risk of developing seropositive RA, with highest inci-
dence rates among first-degree relatives. Among the most influential non genetic 
risk factors there comes smoking. Smoking provides a stimulus to epigenetic 
transformation, particularly in individuals with high-risk RA-susceptibility alleles.
Figure 1. 
Etio-pathogenic factors and disease evolution in rheumatoid arthritis.
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Environmental risk factors also include; particulate exposure, periodontal 
disease, bronchiectasis, diet, obesity and the oral contraceptive impact, respiratory, 
oral, intestinal and genital tract mucosal sites [1, 5], Figure 1.
2.  Role players in the initiation and propagation of autoimmunity in 
rheumatoid arthritis
a. Neo-epitopes generation: genetic and environmental factors operate to ulti-
mately result in the inflammatory and destructive synovial response. Stressors 
including cigarette smoke can act on cells in mucosal sites and promote post-
translational conversion of the amino acid arginine to citrulline in a range of 
proteins, including intracellular proteins (such as histones) and matrix pro-
teins (for example, fibronectin, collagen, fibrinogen, enolase and vimentin) 
via induction of peptidyl arginine deaminases in a process called citrullination 
(also known as deimination) rendering them antigenic [6–8].
Citrullination may also be induced by the oral microbiota: P. gingivalis, com-
mon in periodontal disease which expresses peptidyl arginine deiminases 
and can induce citrullination. A. actinomycetemcomitans, also producing 
a toxin that increases calcium influx into neutrophils, can lead to citrul-
lination of peptides and has been recently implicated in RA etiology. Post-
translational modifications (citrullination, carbamylation, and acetylation) 
are potentially capable of generating neo-epitopes (neo-peptide antigens). 
Animal and human data about autoimmunity in rheumatoid arthritis sug-
gest a model in which multiple environmental influences mucosal immune 
function promoting epigenetic transformations with trafficking of pro-
inflammatory PAMPs making use of the enhanced mucosal permeability. 
Hence, the initial shift towards autoimmunity may present at mucosal sites 
as reported in previous researches with sputum samples positive for ACPA-
IgA and IgG [9, 10].
b. Major histocompatibility complex binding and peptide presentation:  
specific class II human leukocyte antigen (HLA; also known as major histo-
compatibility complex—MHC) loci, which encode MHC molecules HLA-
DRB1*01 and HLA-DRB1*04 display a very strong association with RA. The 
altered peptides bind to MHC protein heterodimers on antigen presenting 
cells, especially those containing the shared epitope [a specific amino acid 
motif QKRAA commonly encoded by some alleles of the HLA-antigen 
D-related (DR) locus significantly associated with the risk of developing 
RA]. Being bound to MHC complex the antigenic epitope gets presented 
by the antigen-presenting cells (dendritic cells and macrophages) to the 
antigen-specific T lymphocyte receptor to stimulate T lymphocyte activation 
and differentiation. Over 100 non-HLA genetic risk factors (loci) including 
polymorphisms of PTPN22, TRAF1-C5, STAT4, TNFAIP3, and PADI4 have 
been associated with an increased risk of developing RA [11, 12].
c. The adaptive immune system: the activated T lymphocyte stimulates the 
release of pro-inflammatory cytokines including RANKL, TNF-α, GM-CSF, 
IL-2, IL-17 and IFN-γ. The antigen-stimulated T lymphocyte then promotes 
B cell priming via T-B cell receptor signaling pathways then stimulate 
specific antibody responses by the stimulated B lymphocytes against the 
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neo-epitopes (neo-antigens) promoting a self-directed immune response. In 
addition to autoantibody production the activated B lymphocytes releases 
IL-6 [13, 14].
d. In situ activation of stromal cells: fibroblast-like synoviocytes FLS, antigen 
presenting cells and macrophages within the synovial joints gets similarly and 
synchronously stimulated to release a cascade of pro-inflammatory mediators 
promoting arthritis with cartilage and bone damage.
FLS masters the intra-articular production of prodigious amounts of MMPs 
and small-molecule mediators such as MMPs, prostaglandins, leukotrienes, 
and RANKL. They additionally express IL-6 receptors and specific patterns of 
microRNAs that could contribute to their activated phenotype. FLS exhibit an 
invasive phenotype that is responsible for cartilage damage and can potentially 
migrate from joint to joint to propagate disease. The macrophages like syn-
oviocytes participate actively via local release of TNF-α, IL-1, IL-6, IL-8 and 
chemokines (CCL19, CCL21) [15–17].
e. Ectopic germinal centers: the adaptive immune cells infiltrate the synovial sub-
lining with almost half of the sublining cells CD4+ memory T cells that can either 
diffusely infiltrate the tissue or, in 15–20% of patients, form ectopic germinal 
centers in which mature B cells proliferate, differentiate and produce antibodies 
(rheumatoid factor RF and anti-citrullinated C peptide ACCP) [18, 19].
Figure 2. 
Proximal interphalangeal joint with macrophages, dendritic cell, T cell, B cells infiltrates with hypertrophied 
synovium, intra-synovial angiomatoids and pannus formation. “By Dr. Maya H Ibrahim” the original image 
provider.
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The development of manifest disease in rheumatoid susceptible patients usually 
requires a second hit driven by cross-reactivity, or molecular mimicry to pathogen-
specific antigens, in the settings of an inevitable lag of pathogen-immune complex 
clearance (Figure 2).
3. Diagnosis of rheumatoid arthritis
The diagnosis of rheumatoid arthritis requires the integration of proper history 
taking, careful clinical examination and investigations. Patients might face a period 
of delay in establishing their diagnosis from weeks to months due to incomplete 
or intermittent symptoms, defective/unaccomplished clinical/radiographic and 
laboratory assessments particularly with early disease [20].
4. Patients’ journey to diagnosis
Standard of care in rheumatoid arthritis aims at the following [21]:
• Establishing early diagnosis of RA.
• Identifying arthritis in need of treatment.
• Designing the ideal way to successfully initiate synthetic non biologic 
DMARDS.
• Providing low remission rates with standard DMARDs.
• Identifying other potential therapeutic targets in aggressive disease.
• Ensuring availability and safety of biologic DMARDS.
• Providing standardized measures for patient assessment, follow-up and treat-
ment modulation.
The recently adopted American College of Rheumatology/European League 
Against Rheumatism ACR/EULAR classification criteria were established in 2010 
with the aim to identify patients with early inflammatory arthritis that is mostly 
due to rheumatoid arthritis. They have been proposed by the faculty as classifica-
tion rather than diagnostic criteria to facilitate stratifying patients with similar 
characteristics for clinical research studies particularly clinical trials with intent to 
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treat. The development of diagnostic criteria for RA as other autoimmune disorders 
is still challenged by inter/intra-individual variability and chances of misdiagnosis. 
However, the current criteria might be used to inform diagnostic decision making in 
clinical practice [22].
5. ACR/EULAR 2010 classification criteria for rheumatoid arthritis
The classification criteria proposed by the American College of Rheumatology/
European League Against Rheumatism (ACR/EULAR) included clinical and sero-
logical variables that can be applied only to individuals with ≥1 swollen joint [22].
5.1 Joint involvement and distribution: 0–5 points
Any swollen or tender joint (excluding the distal interphalangeal joints of hands 
and feet, the first metatarsophalangeal joints and the first carpometacarpal joints) 
on clinical examination; additional evidence from MRI or ultrasonography may be 
used to identify additional joints.
1 large joint (shoulder, elbow, hip, knee or ankle): 0 points
2–10 large joints: 1 point
1–3 small joints (the metacarpophalangeal joint, the proximal interphalangeal 
joint, the second to fifth metatarsophalangeal joints, the interphalangeal joint of the 
thumb and the wrist): 2 points
4–10 small joints: 3 points
>10 joints (of which ≥1 is a small joint): 5 points
Additional small joints include the temporomandibular joint, sternoclavicular 
joint, acromio-clavicular joint and others, as reasonably expected in RA.
5.2 Symptom duration: 0–1 points
This variable refers to the patient’s self-report on the maximum duration of signs 
and symptoms of any joint that is clinically involved at the time of assessment.
<6 weeks: 0 points
≥6 weeks: 1 point.
5.3 Serology (according to respective laboratory standards): 0–3 points
Negative for RF (equal or less than upper limit of normal) and negative for 
ACPA: 0 points
Low-positive for RF (>1–3 times upper limit of normal) or low-positive for 
ACPA: 2 points
High-positive for RF(>3 times upper limit of normal) or high-positive for ACPA: 
3 points.
5.4 Acute-phase reactants (according to local laboratory standards): 0–1 points
Normal CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) 
levels: 0 points
Abnormal CRP levels or abnormal ESR: 1 point
A score of ≥6 points is required for classification as definite rheumatoid 
arthritis (RA).
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6. Disease activity scoring in rheumatoid arthritis
Scoring 
system












≤3.3 >3.3–11 >11–26 >26
CDAI SJC28 + TJC28 + PGA + EGA ≤2.8 >2.8–10 >10–22 >22
DAS Complex formula including the 
Ritchie index, SJC44, ESR and GH
≤1.6 >1.6–2.4 >2.4–3.7 >3.7
DAS28 Complex formula including the 
TJC28, SJC28, ESR (or CRP) and 
GH
≤2.6 >2.6–3.2 >3.2–5.1 >5.1
CDAI, Clinical Disease Activity Index; CRP, C-reactive protein (in SDAI in mg per dl); DAS, Disease Activity 
Score; DAS28, DAS using 28-joint counts; EGA, Evaluator Global Assessment (on a 0–10 cm scale); ESR, 
erythrocyte sedimentation rate; GH, global health (that is, patient global assessment); PGA, patient global 
assessment (on a 0–10 cm scale); RA, rheumatoid arthritis; SDAI, Simplified Disease Activity Index; SJC, swollen 
joint count (the number indicates the number of joints taken into account); TJC, tender joint count (the number 
indicates the number of joints taken into account) [23–25].
7. Different definitions of remission
7.1 American Rheumatism Association
Five or more must be fulfilled for at least two consecutive months—morning 
stiffness not exceeding 15 minutes—no fatigue—no joint pain (by history)—no joint 
tenderness or pain on motion—no soft tissue swelling in joints or tendon sheaths—
ESR (W) < 30 mm/h (f); <20 mm/h (m) [26].
 7.2 DAS/DAS 28 threshold for remission
For the DAS: Ritchie joint index and 44 swollen joint count with either ESR or 
CRP versions, remission: <1.6
For the DAS28: 28 tender and swollen joint count with either ESR or CRP 
 versions, remission: <2.6 [27].
7.3 SDAI/CDAI remission
SDAI = (28TJC) + (28SJC) + MDGA + PtGA + CRP*
CDAI = (28TJC) + (28SJC) + MDGA + PtGA*
SDAI remission ≤3.3** × CDAI remission ≤2.8** [28, 29].
7.4 Boolean definitions
Depend on meeting a (low) level in each of a series of separate disease activity 
measures Boolean-based definition at any time point, a patient must satisfy all of 
the following—Tender Joint Count ≤1—Swollen Joint Count ≤1—CRP ≤1 mg/dL—
Patient Global Assessment ≤1 (on a 0–10 scale) [30].
7.5 ACR-EULAR 2011 definition of remission
• For clinical trials: Boolean—SJC, TJS, PtGA, CRP all ≤1 or index-based—
SDAI ≤3.3 [30]
7
Introductory Chapter: Rheumatoid Arthritis - Overview of Current Facts and Strategies
DOI: http://dx.doi.org/10.5772/intechopen.92771
• For clinical practice: Boolean—SJC, TJC, PtGA all ≤1 or index-based—CDAI 
≤2.8
Factors that contribute to poor prognosis in rheumatoid arthritis include the 
following [25]:
• Persistently moderate or high disease activity despite conventional synthetic 
DMARD (csDMARD) therapy according to composite measures including 
joint counts.
• High acute phase reactant levels.
• High swollen joint count.
• Presence of RF and/or ACPA, especially at high levels.
• Presence of early erosions.
• Failure of two or more csDMARDs.
8. The treat-to-target in rheumatoid arthritis
The treatment paradigm in rheumatoid arthritis has experienced a dramatic shift in 
the latest two decades. Recently, the strategy changed from a treat to relief to a treat to 
target. The current approaches in RA are concerned with early aggressive intervention 
with one or more conventional or traditional synthetic DMARDs (cs/tsDMARDs) and/
or biologic DMARDs (bDMARDs) either as mono or combination therapy, in addition 
to symptomatic anti-inflammatory therapy (NSAIDs, low-dose prednisone). This tight 
control policy aims to; normalize, sustain or maximize physical functionality via retar-
dation or arrest of joint damage. The treat-to-target is the currently established man-
agement approach in the international recommendations provided by ACR, EULAR 
and the Asia Pacific League of Associations for Rheumatology [31, 32], Figure 3.
Recent update on the guidelines of management of rheumatoid arthritis as 
provided by the EULAR European League Against Rheumatism in 2019 announcing 
the following overarching principles [33]:
Figure 3. 
Identified synthetic and biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis.
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• Treatment of patients with RA should target the best care and must be based 
on a shared decision between the RA patient and the rheumatologist.
• Disease activity, structural damage, patient safety, and other comorbidities, 
including the risk for thromboembolism must be considered when prescribing 
treatment.
• Rheumatologists are responsible for the primary care of the patient as they 
possess the optimal depth and breadth of experience regarding the use of all 
types of DMARDs, including efficacy, outcomes, risk assessment and knowl-
edge of comorbidities.
• The heterogeneous nature of rheumatoid arthritis mandates patients’ access 
to effective disease modifying anti-rheumatic drugs with successful multiple 
mechanisms of action.
• RA incurs high individual, medical and societal costs, should be considered 
while prescribing therapy by the rheumatologist.
8.1 EULAR 2019 recommendations
In 2019 the EULAR taskforce stated a number of updated recommendations 
emphasizing the strategy to start DMARDs therapy as soon as the diagnosis of RA is 
made. These recommendations included [33]:
• Treatment should be aimed at reaching a target of sustained remission or low 
disease activity in every patient. Adopted definitions for disease activity states 
assessment and therapy include: (a) remission ACR-EULAR remission defini-
tion—Boolean or index based, (b) low disease activity state according to any of 
the validated composite disease activity measures that include joint counts moder-
ate and high disease activity, and (c) respective disease activity state according to 
any of the validated composite disease activity measures that include joint counts.
• Monitoring should be frequent in active disease (every 1–3 months); if there is 
no improvement by at most 3 months after the start of treatment or the target 
has not been reached by 6 months, therapy should be adjusted.
• Methotrexate MTX should be part of the first treatment strategy—the anchor 
drug.
• In patients with a contraindication to MTX (or early intolerance), leflunomide 
or sulfasalazine should be considered as part of the (first) treatment strategy.
• Short-term glucocorticoids should be considered when initiating or chang-
ing csDMARDs, in different dose regimens and routes of administration, but 
should be tapered as rapidly as clinically feasible.
• If the treatment target is not achieved with the first csDMARD strategy, in the 
absence of poor prognostic factors, other csDMARDs should be considered.
• If the treatment target is not achieved with the first csDMARD strategy, when and 
poor prognostic factors are present, a bDMARD or a tsDMARD should be added.
• Biologic DMARDs and traditional synthetic DMARDs (tsDMARDs) should 
be combined with a csDMARD; in patients who cannot use csDMARDs as 
9
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comedication, IL-6 pathway inhibitors and tsDMARDs may have some advan-
tages compared with other bDMARDs.
• If a bDMARDs or tsDMARDs has failed, treatment with another bDMARD† 
or a tsDMARD‡ should be considered; if one TNF inhibitor therapy has failed, 
patients may receive an agent with another mode of action or a second TNF 
inhibitor.
• If a patient is in persistent remission after having tapered glucocorticoids, one 
can consider tapering bDMARDs or tsDMARDs, especially if this treatment is 
combined with a csDMARD.
• If a patient is in persistent remission, tapering the csDMARD could be 
considered.
9. Summary
• Establish early diagnosis of rheumatoid arthritis.
• Identify patients with arthritis in need for treatment.
• Arrange for evidence-based management.
• Apply aggressive measures to target disease.
• Apply standardized measures for assessment of disease activity, functional 
assessment, patient and physician global assessment.
• Tailoring of therapy with potential consideration of patient safety, comorbidi-
ties and costs.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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